Bringing Precision to Psychiatry: Pioneering Genetic CDx-Use in Major Depressive Disorder
Time: 2:00 pm
day: Day 2 - Track A (2)
Details:
- The Unmet Need in Psychiatry: Psychiatry has lagged behind oncology and immunology in adopting CDx, despite the clear potential to address the biological heterogeneity of disorders like MDD
- Our Innovative CDx Platform anticify™: Using statistical genetics, we’ve developed tools to stratify MDD patients into biologically distinct subtypes, enabling personalised treatment strategies
- Clinical Validation of CDx in Psychiatry: Post-hoc analysis shows our CDx candidate accurately predict responses to CRHR1 antagonists, breathing new life into previously shelved treatments
- IVDR’s impact on a small EU biotech company codeveloping Rx + CDx :Change of study design to dodge IVDR requirements (pivoting to a prospective-retrospective approach); Choosing UK over EU as study location
- The Future Vision: With ongoing clinical programs for Cortibon and Nelivabon, our work sets the stage for applying CDx across psychiatry
